These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37166894)

  • 21. MULTIPLE KERATINOCYTIC CANCERS AFTER INTAKE OF ANTIHYPERTENSIVES (LISINOPRIL/BISOPROLOL/HCT) AND ANTIARRHYTMICS (PROPAFENONE): THE IMPORTANT NEW LINKS TO THE NITROSO-CONTAMINATION AND THE METABOLIC REPROGRAMMING OF THE FUTURE CANCER CELL.
    Tchernev G; Ivanov L; Broshtilova V
    Georgian Med News; 2024 Jun; (351):65-71. PubMed ID: 39230223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EDUCATION FROM DERMATOLOGISTS: THE SIMULTANEOUSLY DEVELOPMENT OF 16 KERATINOCYTIC CANCERS AFTER USE OF METFORMIN IN COMBINATION WITH LOSARTAN/ HYDROCHLOROTHIAZIDE, METOPROLOL AND NIFEDIPINE- IMPORTANT LINKS TO DRUG RELATED (PHOTO)-NITROSO-CARCINOGENESIS AND ONCOPHARMACOGENESIS.
    Tchernev G; Dimova D
    Georgian Med News; 2024 Feb; (347):136-141. PubMed ID: 38609130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data.
    Thresher A; Foster R; Ponting DJ; Stalford SA; Tennant RE; Thomas R
    Regul Toxicol Pharmacol; 2020 Oct; 116():104749. PubMed ID: 32777431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MUSTARDE ROTATION FLAP AS ADEQUATE OPTION FOR HIGH-RISK BCC NEAR THE LOWER EYE LID: THE ADDITIONAL INTAKE OF N-NITROSO-FOLIC-ACID AND N-NITROSO-RIVOROXABAN AS COFACTORS/TRIGGERS OF THE METABOLIC REPROGRAMMING OF THE FUTURE CANCER CELL.
    Tchernev G; Ivanov L
    Georgian Med News; 2024 Jun; (351):131-137. PubMed ID: 39230235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DRUG RELATED NITROSOGENESIS, PHOTOCARCINOGENESIS AND ONCOPHARMACOGENESIS OF NODULAR MELANOMA: A CASE RELATED ANALYSIS CONCERNING THE POLYCONTAMINATION OF THE POLYMEDICATION WITH VALSARTAN/HYDROCHLOROTHIAZIDE AND BISOPROLOL.
    Tchernev G; Broshtilova V; Ivanov L; Alexandrov A; Smilov N; Kordeva S
    Georgian Med News; 2024 Feb; (347):24-27. PubMed ID: 38609108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA).
    Kruhlak NL; Schmidt M; Froetschl R; Graber S; Haas B; Horne I; Horne S; King ST; Koval IA; Kumaran G; Langenkamp A; McGovern TJ; Peryea T; Sanh A; Siqueira Ferreira A; van Aerts L; Vespa A; Whomsley R
    Regul Toxicol Pharmacol; 2024 Jun; 150():105640. PubMed ID: 38754805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product
    Dobo KL; Kenyon MO; Dirat O; Engel M; Fleetwood A; Martin M; Mattano S; Musso A; McWilliams JC; Papanikolaou A; Parris P; Whritenour J; Yu S; Kalgutkar AS
    Chem Res Toxicol; 2022 Mar; 35(3):475-489. PubMed ID: 35212515
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals.
    Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Rojsitthisak P
    Saudi Pharm J; 2023 Feb; 31(2):295-311. PubMed ID: 36942272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults.
    Ferrante di Ruffano L; Dinnes J; Chuchu N; Bayliss SE; Takwoingi Y; Davenport C; Matin RN; O'Sullivan C; Roskell D; Deeks JJ; Williams HC;
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD013187. PubMed ID: 30521689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KARAPANDZIC FLAP FOR SQUAMOUS CELL CARCINOMA OF THE LOWER LIPP: POTENTIAL ROLE OF NITROSAMINES IN EPROSARTAN AS CANCER TRIGGERING FACTORS.
    Tchernev G; Lozev I; Pidakev I; Kordeva S
    Georgian Med News; 2023 Jan; (334):83-85. PubMed ID: 36864798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comprehensive review of sources of nitrosamine contamination of pharmaceutical substances and products.
    Akkaraju H; Tatia R; Mane SS; Khade AB; Dengale SJ
    Regul Toxicol Pharmacol; 2023 Mar; 139():105355. PubMed ID: 36792049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Approaches to cancer prevention based on an understanding of N-nitrosamine carcinogenesis.
    Hecht SS
    Proc Soc Exp Biol Med; 1997 Nov; 216(2):181-91. PubMed ID: 9349687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genotoxicity evaluation of nitrosamine impurities using human TK6 cells transduced with cytochrome P450s.
    Li X; He X; Le Y; Guo X; Bryant MS; Atrakchi AH; McGovern TJ; Davis-Bruno KL; Keire DA; Heflich RH; Mei N
    Arch Toxicol; 2022 Nov; 96(11):3077-3089. PubMed ID: 35882637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic Activation and DNA Interactions of Carcinogenic
    Li Y; Hecht SS
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nitrosamine Impurities in Angiotensin Receptor Blockers.
    Shephard EA; Nawarskas JJ
    Cardiol Rev; 2020; 28(5):262-265. PubMed ID: 32467427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Permitted daily exposure limits for noteworthy N-nitrosamines.
    Johnson GE; Dobo K; Gollapudi B; Harvey J; Kenny J; Kenyon M; Lynch A; Minocherhomji S; Nicolette J; Thybaud V; Wheeldon R; Zeller A
    Environ Mol Mutagen; 2021 Jun; 62(5):293-305. PubMed ID: 34089278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Presence of nitrosamine impurities in medicinal products.
    Sedlo I; Kolonić T; Tomić S
    Arh Hig Rada Toksikol; 2021 Mar; 72(1):1-5. PubMed ID: 33787187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The EU Response to the Presence of Nitrosamine Impurities in Medicines.
    Ruepp R; Frötschl R; Bream R; Filancia M; Girard T; Spinei A; Weise M; Whomsley R
    Front Med (Lausanne); 2021; 8():782536. PubMed ID: 34869504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of less-than-lifetime (LTL) durational limits for nitrosamines: Case study of N-Nitrosodiethylamine (NDEA).
    Bercu JP; Masuda-Herrera M; Johnson G; Czich A; Glowienke S; Kenyon M; Thomas R; Ponting DJ; White A; Cross K; Waechter F; Rodrigues MAC
    Regul Toxicol Pharmacol; 2021 Jul; 123():104926. PubMed ID: 33862169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.